GlassScriptPhysician profile
Dalitza M Alvarez Valentin
NPI 1225325574
$10,675.79
in general payments reported to CMS, 2019-2025
18 companies · $755 in 2025
The $755 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,004 · 2020: $1,634 · 2021: $1,357 · 2022: $1,375 · 2023: $929 · 2024: $1,622 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,562 · Travel and Lodging: $646 · Education: $97.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,562.39 |
| Travel and Lodging | $645.84 |
| Education | $97.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,170.07 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $1,678.84 | 2019-2023 | Janumet, Steglujan, Segluromet |
| Novo Nordisk INC | $1,263.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,260.15 | 2020-2025 | Jardiance |
| Medtronic, INC. | $898.98 | 2019-2024 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $675.39 | 2019-2024 | Lokelma, Farxiga |
| Sanofi-Aventis U.S. LLC | $662.11 | 2019-2023 | |
| Amgen INC. | $479.93 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $398.74 | 2019-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $314.71 | 2021-2022 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $212.76 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Puerto Rico INC. | $191.45 | 2023-2025 | Kerendia |
| Dexcom, INC. | $120.00 | 2021-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $113.87 | 2019-2025 | |
| Lilly USA, LLC | $90.14 | 2024-2025 | Jardiance |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $65.74 | 2025 | Tymlos |
| Pbg Puerto Rico LLC | $49.22 | 2021-2022 | |
| Gilead Sciences, INC. | $30.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dalitza Alvarez Valentin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.